Regeneron (REGN) Tops Q3 EPS by 40c; EYLEA Sales Rose 16%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
Regeneron Pharma (REGN) PT Cut at Baird on 'Uneventful Earnings'
November 4, 2016 12:40 PM EDTBaird analyst Brian Skorney lowered his price target on Neutral-rated Regeneron Pharma (NASDAQ: REGN) to $379.00 (from $448.00) following "uneventful earnings."
Skorney commented, "Though earnings were relatively uneventful and the company pulled out an EPS beat on lower operating expenses, Eylea growth continues to... More
